Metformin and Parthenolide Combination Synergistically Induces Apoptosis, Inhibits Angiogenesis in Breast Cancer Mice
Background
Despite advances, breast cancer remains a leading cause of cancer-related mortality, often requiring aggressive treatments with significant side effects and limited long-term efficacy for advanced stages. There is a critical need for novel therapeutic strategies that are both effective and well-tolerated. Metformin (MET), a common antidiabetic drug, and parthenolide (PAR), a natural anti-inflammatory compound, have independently shown promising anticancer properties. This study explores their combined potential to enhance therapeutic outcomes by targeting key cancer pathways like apoptosis and angiogenesis.
Study Design
Researchers evaluated the antiproliferative effects of metformin, parthenolide, and their combination against EMT6/P, MDA-MB-231, and T47D breast cancer cell lines using the MTT assay. Synergistic interactions were quantified via the isobolographic method to calculate the combination index (CI). In T47D cells, caspase-3 activity assays assessed apoptosis, and VEGF levels measured angiogenesis. For in vivo studies, EMT6/P cells were inoculated into BALB/c mice, which then received MET, PAR, or combination therapy. Tumor size was monitored, and treatment-related toxicity was assessed by measuring serum AST, ALT, and creatinine levels.
Results
The combination of metformin and parthenolide demonstrated a clear synergistic antiproliferative interaction across all tested breast cancer cell lines. In vivo, combination therapy led to a significant reduction in tumor size, achieving a 50% cure rate with zero treatment-related mortality. This synergistic effect was attributed to specific molecular mechanisms: > The combination significantly induced caspase-3-dependent apoptosis and reduced VEGF expression compared to either agent administered alone. Importantly, serum AST, ALT, and creatinine levels in combination-treated tumor-bearing mice remained within normal ranges, indicating a favorable safety profile for this regimen.
Key Findings
- Metformin and parthenolide exhibited synergistic antiproliferative effects across multiple breast cancer cell lines.
- Combination therapy significantly reduced tumor size in mice, achieving a 50% cure rate.
- The combination induced
caspase-3-dependent apoptosis more effectively than single agents. - Combination therapy significantly reduced
VEGFexpression, indicating angiogenesis inhibition. - Combination treatment showed zero treatment-related mortality and maintained normal liver/kidney function markers.
Why It Matters
This study highlights a promising, well-tolerated combination therapy for breast cancer, leveraging metformin's metabolic effects and parthenolide's anti-inflammatory properties to synergistically induce apoptosis and inhibit angiogenesis. For individuals exploring novel cancer support strategies, this preclinical data suggests a potential for enhanced efficacy with reduced toxicity compared to single-agent approaches. While still in early stages, these findings warrant further investigation into clinical translation, potentially informing future adjuvant or standalone protocols that could improve patient outcomes and quality of life by targeting multiple cancer hallmarks simultaneously.
metformin
parthenolide
breast-cancer
apoptosis
angiogenesis
preclinical-animal